Abstract
Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disease in adults. CLL is diagnosed when the count of monoclonal B-lymphocytes in peripheral blood exceeds 5 × 109/L lasting for at least 3 months. Leukemic cells in the blood, lymph nodes, bone marrow, and also, in the case of severe disease, nonlymphatic organs in 95% of cases have a morphology of mature lymphocytes with CD5+/CD19+/CD23+ phenotype. CLL is characterized by heterogenous clinical course, prognosis and response to treatment. The start of treatment is individual for each patient and depends on the severity of the clinical presentation or progressive nature of the disease. In this article, we present the most important information about epidemiology, diagnostic criteria, clinical classification, prognostic factors, indications for starting treatment, therapy options, criteria of response to the therapy in patients with CLL.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
